Formycon Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 239

Employees

  • Stock Symbol
  • FYB

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $55.04
  • (As of Friday Closing)

Formycon General Information

Description

Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.

Contact Information

Formerly Known As
Nanohale AG, Scil Technology, Scil Technology GmbH
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Fraunhoferstrasse 15
  • Planegg
  • 82152 Martinsried
  • Germany
+49 089
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
ETR
Vertical(s)
Corporate Office
  • Fraunhoferstrasse 15
  • Planegg
  • 82152 Martinsried
  • Germany
+49 089

Formycon Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Formycon Stock Performance

As of 06-Dec-2024, Formycon’s stock price is $55.04. Its current market cap is $972M with 17.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$55.04 $53.72 $40.13 - $64.09 $972M 17.7M 4.71K $4.40

Formycon Financials Summary

As of 30-Jun-2024, Formycon has a trailing 12-month revenue of $65.8M.

In Thousands,
USD
TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 982,098 971,413 1,379,202 699,120
Revenue 65,780 84,073 44,681 43,287
EBITDA 66,542 84,640 40,249 (14,847)
Net Income 69,131 82,016 37,842 (15,713)
Total Assets 1,015,930 984,206 915,503 80,065
Total Debt 11,645 32,594 31,431 5,982
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Formycon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Formycon‘s full profile, request access.

Request a free trial

Formycon Patents

Formycon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4386084-A1 Improved ace2 fusion proteins Pending 14-Dec-2022
EP-4331571-A1 Formulations of ace2-igm fusion proteins Pending 02-Sep-2022
EP-4437112-A1 Improved ace2 fusion proteins Pending 24-Nov-2021
EP-4377452-A2 Ace2 fusion proteins and uses thereof Pending 30-Jul-2021
CA-3220545-A1 Formulations of anti-pd1 antibodies Pending 23-Jun-2021 C07K16/2818
To view Formycon’s complete patent history, request access »

Formycon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Formycon Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Formycon‘s full profile, request access.

Request a free trial

Formycon Investments & Acquisitions (4)

Formycon’s most recent deal was a Merger/Acquisition with Bioeq (Zug) for . The deal was made on 10-May-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bioeq (Zug) 10-May-2022 Merger/Acquisition Pharmaceuticals
FYB 202 01-May-2022 Merger/Acquisition Biotechnology
FYB 202 22-Dec-2017 Joint Venture Biotechnology
Scil Technology (R&D & Service Units) 31-Dec-2011 Merger/Acquisition Discovery Tools (Healthcare)
To view Formycon’s complete investments and acquisitions history, request access »

Formycon ESG

Risk Overview

Risk Rating

Updated April, 24, 2024

26.95 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,100

Rank

Percentile

Pharmaceuticals

Industry

of 851

Rank

Percentile

Biotechnology

Subindustry

of 367

Rank

Percentile

To view Formycon’s complete esg history, request access »

Formycon FAQs

  • When was Formycon founded?

    Formycon was founded in 1999.

  • Where is Formycon headquartered?

    Formycon is headquartered in Martinsried, Germany.

  • What is the size of Formycon?

    Formycon has 239 total employees.

  • What industry is Formycon in?

    Formycon’s primary industry is Pharmaceuticals.

  • Is Formycon a private or public company?

    Formycon is a Public company.

  • What is Formycon’s stock symbol?

    The ticker symbol for Formycon is FYB.

  • What is the current stock price of Formycon?

    As of 06-Dec-2024 the stock price of Formycon is $55.04.

  • What is the current market cap of Formycon?

    The current market capitalization of Formycon is $972M.

  • What is Formycon’s current revenue?

    The trailing twelve month revenue for Formycon is $65.8M.

  • What is Formycon’s annual earnings per share (EPS)?

    Formycon’s EPS for 12 months was $4.40.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »